Last reviewed · How we verify
Propranolol+pyridostigmine
Propranolol blocks beta-adrenergic receptors to reduce heart rate and blood pressure, while pyridostigmine inhibits acetylcholinesterase to increase acetylcholine levels and enhance neuromuscular transmission.
Propranolol blocks beta-adrenergic receptors to reduce heart rate and blood pressure, while pyridostigmine inhibits acetylcholinesterase to increase acetylcholine levels and enhance neuromuscular transmission. Used for Myasthenia gravis with cardiac manifestations, Thyroid storm with neuromuscular complications.
At a glance
| Generic name | Propranolol+pyridostigmine |
|---|---|
| Sponsor | Seoul National University Hospital |
| Drug class | Beta-blocker + Acetylcholinesterase inhibitor combination |
| Target | Beta-adrenergic receptors; Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neurology; Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This combination leverages propranolol's sympathetic nervous system suppression to manage cardiovascular symptoms, while pyridostigmine enhances parasympathetic signaling by preventing acetylcholine breakdown. Together, they address both adrenergic hyperactivity and neuromuscular dysfunction, commonly used in conditions like myasthenia gravis with concurrent cardiac symptoms or thyroid storm management.
Approved indications
- Myasthenia gravis with cardiac manifestations
- Thyroid storm with neuromuscular complications
Common side effects
- Bradycardia
- Hypotension
- Muscle cramps
- Increased salivation
- Bronchospasm
- Fatigue
Key clinical trials
- Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Propranolol+pyridostigmine CI brief — competitive landscape report
- Propranolol+pyridostigmine updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI